Journal of Clinical Oncology, Vol 15, 1385-1394, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group

PURPOSE: Adjuvant tamoxifen has been shown to reduce relapse and mortality among node-positive post-menopausal breast cancer patients. The value of adding chemotherapy to tamoxifen is controversial. PATIENTS AND METHODS: Between July 1986 and April 1993, 1,266 postmenopausal breast cancer patients with node-positive disease were randomly assigned to receive one of four adjuvant therapy regimens: (A) tamoxifen alone for 5 years; (B) tamoxifen plus three courses of early cyclophosphamide, methotrexate, and fluorouracil (CMF) on months 1, 2, and 3; (C) tamoxifen plus delayed single courses of CMF on months 9, 12, and 15; (D) tamoxifen plus early and delayed CMF on months 1, 2, 3, 9, 12, and 15. The two-by-two factorial design allowed two direct comparisons: early CMF (B and D) versus no early CMF (A and C), and delayed CMF (C and D) versus no delayed CMF (A and B). Estrogen receptor (ER) status was known for all patients and was used to stratify the randomization. A total of 1, 212 patients (96%) were eligible and assessable. The median follow-up duration was 60 months. RESULTS: The results of the two-by-two factorial comparisons were as follows: (1) early CMF added to tamoxifen significantly improved 5-year disease-free survival (DFS; 64% v 57%; hazards ratio [HR], 0.79; 95% confidence interval [CI], 0.66 to 0.95; P = .01); and (2) delayed CMF added to tamoxifen did not improve DFS (5-year DFS, 61% v 60%; HR, 0.97; 95% CI, 0.81 to 1.17; P = .77). For patients with ER-positive tumors, the addition of CMF, either early or delayed or both, reduced the relative risk of relapse by 22% to 36%. In contrast, for patients with ER-negative tumors, tamoxifen with delayed CMF was associated with a nonsignificant increased risk of relapse (HR, 1.27; 95% CI, 0.92 to 1.76; P = .15). CONCLUSION: Postmenopausal patients with node-positive breast cancer should be offered combination chemotherapy in addition to tamoxifen. Tamoxifen should not be initiated before CMF, as this might be detrimental, especially for patients with ER-negative tumors.

This article has been cited by other articles:

				B. C. Pestalozzi, D. Zahrieh, E. Mallon, B. A. Gusterson, K. N. Price, R. D. Gelber, S. B. Holmberg, J. Lindtner, R. Snyder, B. Thurlimann, et al. Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials J. Clin. Oncol., June 20, 2008; 26(18): 3006 - 3014. [Abstract] [Full Text] [PDF]

				P. Karlsson, B. F. Cole, K. N. Price, A. S. Coates, M. Castiglione-Gertsch, B. A. Gusterson, E. Murray, J. Lindtner, J. P. Collins, S. B. Holmberg, et al. The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer J. Clin. Oncol., May 20, 2007; 25(15): 2019 - 2026. [Abstract] [Full Text] [PDF]

				B. C. Pestalozzi, D. Zahrieh, K. N. Price, S. B. Holmberg, J. Lindtner, J. Collins, D. Crivellari, M. F. Fey, E. Murray, O. Pagani, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann. Onc., June 1, 2006; 17(6): 935 - 944. [Abstract] [Full Text] [PDF]

				R. Demicheli, R. Miceli, A. Moliterni, M. Zambetti, W. J. M. Hrushesky, M. W. Retsky, P. Valagussa, and G. Bonadonna Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process Ann. Onc., September 1, 2005; 16(9): 1449 - 1457. [Abstract] [Full Text] [PDF]

				M. Colleoni, S. Li, R. D. Gelber, A. S. Coates, M. Castiglione-Gertsch, K. N. Price, J. Lindtner, C.-M. Rudenstam, D. Crivellari, J. Collins, et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Ann. Onc., May 1, 2005; 16(5): 716 - 725. [Abstract] [Full Text] [PDF]

				M. Colleoni, D. Zahrieh, R. D. Gelber, S. B. Holmberg, J. E. Mattsson, C.-M. Rudenstam, J. Lindtner, D. Erzen, R. Snyder, J. Collins, et al. Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience J. Clin. Oncol., March 1, 2005; 23(7): 1390 - 1400. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Ann. Onc., December 1, 2004; 15(12): 1749 - 1759. [Abstract] [Full Text] [PDF]

				G. Berclaz, S. Li, K. N. Price, A. S. Coates, M. Castiglione-Gertsch, C.-M. Rudenstam, S. B. Holmberg, J. Lindtner, D. Erien, J. Collins, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience Ann. Onc., June 1, 2004; 15(6): 875 - 884. [Abstract] [Full Text] [PDF]

				D. Rayson, D. Chiasson, and R. Dewar Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000 Can. Med. Assoc. J., March 16, 2004; 170(6): 957 - 961. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365. [Abstract] [Full Text] [PDF]

				A. Wallgren, M. Bonetti, R.D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, S.B. Holmberg, J. Lindtner, B. Thurlimann, M. Fey, I.D. Werner, et al. Risk Factors for Locoregional Recurrence Among Breast Cancer Patients: Results From International Breast Cancer Study Group Trials I Through VII J. Clin. Oncol., April 1, 2003; 21(7): 1205 - 1213. [Abstract] [Full Text] [PDF]

				A. C. Wolff and M. D. Abeloff Adjuvant Chemotherapy for Postmenopausal Lymph Node-Negative Breast Cancer: It Ain't Necessarily So J Natl Cancer Inst, July 17, 2002; 94(14): 1041 - 1043. [Full Text] [PDF]

				International Breast Cancer Study Group (IBCSG) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial J Natl Cancer Inst, July 17, 2002; 94(14): 1054 - 1065. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, and H.-J. Senn Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer J. Clin. Oncol., September 15, 2001; 19(18): 3817 - 3827. [Full Text] [PDF]

				D. Ginsburg Chemotherapy for older women with node-positive breast cancer Can. Med. Assoc. J., September 1, 2001; 165(5): 525 - 527. [Full Text]

				G. Vlastos, M. E. Jean, A. N. Mirza, N. Q. Mirza, H. M. Kuerer, F. C. Ames, K. K. Hunt, M. I. Ross, T. A. Buchholz, A. U. Buzdar, et al. Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases Ann. Surg. Oncol., June 1, 2001; 8(5): 425 - 431. [Abstract] [Full Text] [PDF]

				M. Colleoni, A. O'Neill, A. Goldhirsch, R. D. Gelber, M. Bonetti, B. Thurlimann, K. N. Price, M. Castiglione-Gertsch, A. S. Coates, J. Lindtner, et al. Identifying Breast Cancer Patients at High Risk for Bone Metastases J. Clin. Oncol., December 1, 2000; 18(23): 3925 - 3935. [Abstract] [Full Text] [PDF]

				A. S. Coates, C. Hurny, H. F. Peterson, J. Bernhard, M. Castiglione-Gertsch, R. D. Gelber, and A. Goldhirsch Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer J. Clin. Oncol., November 15, 2000; 18(22): 3768 - 3774. [Abstract] [Full Text] [PDF]

				M. Extermann, L. Balducci, and G. H. Lyman What Threshold for Adjuvant Therapy in Older Breast Cancer Patients? J. Clin. Oncol., April 1, 2000; 18(8): 1709 - 1717. [Abstract] [Full Text] [PDF]

				J.A. Wils, J.M. Bliss, M. Marty, G. Coombes, C. Fontaine, F. Morvan, T. Olmos, F.R. Perez-Lopez, P. Vassilopoulos, E. Woods, et al. Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group J. Clin. Oncol., July 1, 1999; 17(7): 1988 - 1988. [Abstract] [Full Text] [PDF]

				F. Cosman and R. Lindsay Selective Estrogen Receptor Modulators: Clinical Spectrum Endocr. Rev., June 1, 1999; 20(3): 418 - 434. [Abstract] [Full Text]

				R. Jakesz, H. Hausmaninger, K. Haider, E. Kubista, H. Samonigg, M. Gnant, D. Manfreda, G. Tschurtschenthaler, R. Kolb, M. Stierer, et al. Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node-Positive Breast Cancer J. Clin. Oncol., June 1, 1999; 17(6): 1701 - 1701. [Abstract] [Full Text] [PDF]

				C. K. Osborne Tamoxifen in the Treatment of Breast Cancer N. Engl. J. Med., November 26, 1998; 339(22): 1609 - 1618. [Full Text] [PDF]

				C. A. Hudis and L. Norton Adjuvant Drug Treatment for Resectable Breast Cancer Oncologist, December 1, 1997; 2(6): 351 - 358. [Abstract] [Full Text] [PDF]